Fate Therapeutics (FATE) Misses Q1 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.38), $0.01 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Marchex (MCHX) Reports In-Line Q2 EPS
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance